Antiviral biomimetic polymers (ABPs) are disclosed that can be used to prevent and/or treat viral disease. The ABPs are discovered by a process involving high-throughput screening of polymer libraries using disease-relevant bioactive molecules as target molecules. ABPs can be nanoscale (termed nanoABPs) or larger. Methods are described for the preparation and use of ABPs as prophylactics and therapeutics (in vivo) and as preventative agents, for example, in personal protective equipment (ex vivo). ABPs can be used to prevent and treat viral diseases including those caused by Filoviridae.

A method for detecting a disease marker using self-amplification of a detection signal is disclosed. The method can include (a) a step of simultaneously inducing an antigen-antibody immune response and an Au particle formation reaction by reduction of Au ions in an assay solution prepared by, to a pre-assay solution in which all of an antibody or antigen for detection of a disease-specific marker, free Au ions, and adsorbed Au ions are present, adding a sample, which contains a disease-specific antigen or antibody binding specifically to the antibody or the antigen, and a reducing agent; and (b) a step of confirming the presence or absence of a disease-specific marker by a chromogenic reaction through the Au particle formation.

Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.

The present invention relates to a chimeric virus particle of potato virus X, said particle having, as a capsid protein, a fusion protein containing a capsid protein and an antigenic determinant of lipocalin, and the use thereof in the in vitro diagnosis of Sjgren's Syndrome using the ELISA method.

The detection and quantification of nucleic acid sequences can be done using template catalyzed TARA transfer reactions without enzyme and PCR. It comes with the novel chemistry platform technology using Template Assisted Rapid Assay (TARA), an enzyme-free, PCR-less and rapid transfer reaction assay directly from samples from nasopharyngeal swab, nasal aspirate, oropharyngeal swab or blood. The procedures of the detection and quantification of nucleic acid sequences include utilizing two or more oligonucleotide probes that reversibly bind a target nucleic acid in close proximity to each other and possess complementary reactive TARA reaction moieties. In addition, various methods, reagents, and kits for detecting and quantifying nucleic acid sequences and for determining the sequence of nucleic acids are provided.

The present invention relates to the preparation and use of copolymers composed of N-(2-hydroxypropyl) methacrylamide (HPMAA) and carboxybetaine methacrylamide (CBMAA). The invention further describes polymer brushes having structure I
SR-polymer(I) wherein S is a substrate; R is a residue of a polymerization initiator or a RAFT agent bound to the substrate; and polymer is the copolymer of N-(2-hydroxypropyl) methacrylamide and carboxybetaine methacrylamide Furthermore, production of these polymer brushes, containing random or block copolymers grafted to or from a substrate is described. The copolymer brushes are suitable for protecting substrates from deposition and/or adhesion of biological substances, and/or against thrombus formation. The brushes functionalized by covalent attachment of bioactive substances to CBMAA monomer units are particularly suitable for specific interaction with target biological substances which is not affected by nonspecific deposition of non-target compounds.

Provided herein are compositions, methods, and kits for detecting human Pegivirus 2 (HPgV-2). In certain embodiments, provided herein are HPgV-2 specific nucleic acid probes and primers, and methods for detecting HPgV-2 nucleic acid. In other embodiments, provided herein are HPgV-2 immunogenic composition compositions, methods of treating a subject with immunogenic HPgV-2 peptides, and methods of detecting HPgV-2 subject antibodies in a sample.

A biomarker composition includes, as an active ingredient, one or at least two polypeptides having 5 to 120 consecutive amino acids that are selected from the group consisting of an amino acid in which serine (S) at the 56.sup.th position is substituted with leucine (L), an amino acid in which serine (S) at the 8.sup.th position is substituted with asparagines (N), an amino acid in which threonine (T) at the 81.sup.st position is substituted with alanine (A), an amino acid in which valine (V) at the 88.sup.th position is substituted with alanine (A), an amino acid in which glycine (G) at the 117.sup.th position is substituted with asparatic acid (D), and an amino acid in which glutamic acid (E) at the 119.sup.th position is substituted with lysine (K), within an amino acid sequence of VHSV represented by SEQ ID NO: 1.

The present disclosure is directed to antibodies binding to and neutralizing ebolavirus and methods for use thereof. The present disclosure is directed to a method of detecting an ebolavirus infection in a subject comprising (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Table 2, or an antibody fragment thereof; and (b) detecting ebolavirus glycoprotein in said sample by binding of said antibody or antibody fragment to antigen in said sample. In still further embodiments, the present disclosure concerns immunodetection kits for use with the immunodetection methods described above.

The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza A virus group 1 subtypes selected from H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and H17 and variants thereof and one or more influenza A virus group 2 subtype selected from H3, H4, H7, H1, 0, H14 and H15 and variants thereof.